Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. 2006

Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, 01605, USA.

Sequence variability associated with human immunodeficiency virus type 1 (HIV-1) is useful for inferring structural and/or functional constraints at specific residues within the viral protease. Positions that are invariant even in the presence of drug selection define critically important residues for protease function. While the importance of conserved active-site residues is easily understood, the role of other invariant residues is not. This work focuses on invariant Thr80 at the apex of the P1 loop of HIV-1, HIV-2, and simian immunodeficiency virus protease. In a previous study, we postulated, on the basis of a molecular dynamics simulation of the unliganded protease, that Thr80 may play a role in the mobility of the flaps of protease. In the present study, both experimental and computational methods were used to study the role of Thr80 in HIV protease. Three protease variants (T80V, T80N, and T80S) were examined for changes in structure, dynamics, enzymatic activity, affinity for protease inhibitors, and viral infectivity. While all three variants were structurally similar to the wild type, only T80S was functionally similar. Both T80V and T80N had decreased the affinity for saquinavir. T80V significantly decreased the ability of the enzyme to cleave a peptide substrate but maintained infectivity, while T80N abolished both activity and viral infectivity. Additionally, T80N decreased the conformational flexibility of the flap region, as observed by simulations of molecular dynamics. Taken together, these data indicate that HIV-1 protease functions best when residue 80 is a small polar residue and that mutations to other amino acids significantly impair enzyme function, possibly by affecting the flexibility of the flap domain.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D014364 Tryptophan An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals. Ardeydorm,Ardeytropin,L-Tryptophan,L-Tryptophan-ratiopharm,Levotryptophan,Lyphan,Naturruhe,Optimax,PMS-Tryptophan,Trofan,Tryptacin,Tryptan,Tryptophan Metabolism Alterations,ratio-Tryptophan,L Tryptophan,L Tryptophan ratiopharm,PMS Tryptophan,ratio Tryptophan
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016282 Aspartic Acid Endopeptidases A sub-subclass of endopeptidases that depend on an ASPARTIC ACID residue for their activity. Aspartic Endopeptidases,Aspartyl Endopeptidases,Acid Endopeptidases, Aspartic,Endopeptidases, Aspartic Acid,Endopeptidases, Aspartyl
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D017433 Protein Structure, Secondary The level of protein structure in which regular hydrogen-bond interactions within contiguous stretches of polypeptide chain give rise to ALPHA-HELICES; BETA-STRANDS (which align to form BETA-SHEETS), or other types of coils. This is the first folding level of protein conformation. Secondary Protein Structure,Protein Structures, Secondary,Secondary Protein Structures,Structure, Secondary Protein,Structures, Secondary Protein
D017434 Protein Structure, Tertiary The level of protein structure in which combinations of secondary protein structures (ALPHA HELICES; BETA SHEETS; loop regions, and AMINO ACID MOTIFS) pack together to form folded shapes. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Tertiary Protein Structure,Protein Structures, Tertiary,Tertiary Protein Structures

Related Publications

Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
June 1989, Journal of virology,
Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
March 1992, Medical hypotheses,
Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
August 2008, Journal of virology,
Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
July 1988, Proceedings of the National Academy of Sciences of the United States of America,
Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
September 1996, Journal of virology,
Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
July 2001, Journal of virology,
Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
January 1991, FEBS letters,
Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
August 1997, Blood,
Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
January 1994, Methods in enzymology,
Jennifer E Foulkes, and Moses Prabu-Jeyabalan, and Deyna Cooper, and Gavin J Henderson, and Janera Harris, and Ronald Swanstrom, and Celia A Schiffer
February 1995, Virology,
Copied contents to your clipboard!